WallStreetZenWallStreetZen

NASDAQ: CTKB
Cytek Biosciences Inc Stock Forecast, Predictions & Price Target

Analyst price target for CTKB

Based on 2 analysts offering 12 month price targets for Cytek Biosciences Inc.
Min Forecast
$8.50+38.21%
Avg Forecast
$9.25+50.41%
Max Forecast
$10.00+62.6%

Should I buy or sell CTKB stock?

Based on 2 analysts offering ratings for Cytek Biosciences Inc.
Strong Buy
Strong Buy
2 analysts 100%
Buy
0 analysts 0%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their CTKB stock forecasts and price targets.

CTKB stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-05-13
lockedlocked$00.00+00.00%2024-02-29

1 of 1

Forecast return on equity

Is CTKB forecast to generate an efficient return?
Company
4.24%
Industry
22.38%
Market
62.08%
CTKB's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is CTKB forecast to generate an efficient return on assets?
Company
3.38%
Industry
11.76%
CTKB is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

CTKB earnings per share forecast

What is CTKB's earnings per share in the next 3 years based on estimates from 4 analysts?
Avg 1 year Forecast
-$0.06
Avg 2 year Forecast
$0.01
Avg 3 year Forecast
$0.13

CTKB revenue forecast

What is CTKB's revenue in the next 3 years based on estimates from 6 analysts?
Avg 1 year Forecast
$207.7M+3.46%
Avg 2 year Forecast
$246.9M+22.97%
Avg 3 year Forecast
$289.0M+43.92%
CTKB's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

CTKB revenue growth forecast

How is CTKB forecast to perform vs Medical Devices companies and vs the US market?
Company
11.13%
Industry
8.14%
Market
10.56%
CTKB's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
CTKB's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

CTKB vs Medical Device Stocks

TickerPricePrice TargetUp/downsideConsensus
CTKB$6.15$9.25+50.41%Strong Buy
CATX$12.64$21.00+66.14%Strong Buy
KIDS$32.57$38.40+17.90%Buy
SIBN$16.61$25.67+54.53%Strong Buy
FNA$8.10$16.75+106.79%Strong Buy

Cytek Biosciences Stock Forecast FAQ

Is Cytek Biosciences Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: CTKB) stock is to Strong Buy CTKB stock.

Out of 2 analysts, 2 (100%) are recommending CTKB as a Strong Buy, 0 (0%) are recommending CTKB as a Buy, 0 (0%) are recommending CTKB as a Hold, 0 (0%) are recommending CTKB as a Sell, and 0 (0%) are recommending CTKB as a Strong Sell.

If you're new to stock investing, here's how to buy Cytek Biosciences stock.

What is CTKB's earnings growth forecast for 2024-2026?

(NASDAQ: CTKB) Cytek Biosciences's forecast annual earnings growth rate of N/A is not forecast to beat the US Medical Devices industry's average forecast earnings growth rate of 30.35%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 20.45%.

Cytek Biosciences's earnings in 2024 is -$11,510,000.On average, 4 Wall Street analysts forecast CTKB's earnings for 2024 to be -$7,548,193, with the lowest CTKB earnings forecast at -$14,440,022, and the highest CTKB earnings forecast at $0. On average, 3 Wall Street analysts forecast CTKB's earnings for 2025 to be $1,745,930, with the lowest CTKB earnings forecast at -$2,625,459, and the highest CTKB earnings forecast at $9,189,105.

In 2026, CTKB is forecast to generate $16,632,280 in earnings, with the lowest earnings forecast at $9,189,105 and the highest earnings forecast at $26,254,586.

What is CTKB's revenue growth forecast for 2024-2026?

(NASDAQ: CTKB) Cytek Biosciences's forecast annual revenue growth rate of 11.13% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 8.14%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.56%.

Cytek Biosciences's revenue in 2024 is $200,786,000.On average, 6 Wall Street analysts forecast CTKB's revenue for 2024 to be $27,270,638,270, with the lowest CTKB revenue forecast at $26,871,568,566, and the highest CTKB revenue forecast at $27,573,878,736. On average, 3 Wall Street analysts forecast CTKB's revenue for 2025 to be $32,411,286,170, with the lowest CTKB revenue forecast at $31,203,575,223, and the highest CTKB revenue forecast at $33,549,422,465.

In 2026, CTKB is forecast to generate $37,935,251,022 in revenue, with the lowest revenue forecast at $36,415,110,505 and the highest revenue forecast at $40,502,949,514.

What is CTKB's forecast return on assets (ROA) for 2024-2026?

(NASDAQ: CTKB) forecast ROA is 3.38%, which is lower than the forecast US Medical Devices industry average of 11.76%.

What is CTKB's Price Target?

According to 2 Wall Street analysts that have issued a 1 year CTKB price target, the average CTKB price target is $9.25, with the highest CTKB stock price forecast at $10.00 and the lowest CTKB stock price forecast at $8.50.

On average, Wall Street analysts predict that Cytek Biosciences's share price could reach $9.25 by May 13, 2025. The average Cytek Biosciences stock price prediction forecasts a potential upside of 50.41% from the current CTKB share price of $6.15.

What is CTKB's Earnings Per Share (EPS) forecast for 2024-2026?

(NASDAQ: CTKB) Cytek Biosciences's current Earnings Per Share (EPS) is -$0.09. On average, analysts forecast that CTKB's EPS will be -$0.06 for 2024, with the lowest EPS forecast at -$0.11, and the highest EPS forecast at $0.00. On average, analysts forecast that CTKB's EPS will be $0.01 for 2025, with the lowest EPS forecast at -$0.02, and the highest EPS forecast at $0.07. In 2026, CTKB's EPS is forecast to hit $0.13 (min: $0.07, max: $0.20).

What is CTKB's forecast return on equity (ROE) for 2024-2026?

(NASDAQ: CTKB) forecast ROE is 4.24%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.